ONO-3403

• Description :

  ONO-3403 is an orally active serine protease inhibitor. ONO-3403 inhibits the production of TNF-α and nitric oxide induced by LPS. ONO-3403 inhibits the cell growth and induces the apoptosis, and has an antitumor effect on malignant tumors[1][2][3][4].

• UNSPSC :

  12352005

• Target :

  Apoptosis; Ser/Thr Protease

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Metabolic Enzyme/Protease

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/ono-3403.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(C1=CC=C(C=C1)/C=C(C(N(CC=C)CC(OCC)=O)=O)\C)OC2=CC=C(C=C2)C(N)=N.CS(=O)(O)=O

• Molecular Formula :

  C26H31N3O8S

• Molecular Weight :

  545.60

• References & Citations :

  [1]Tumurkhuu G, et al. ONO 3403, a synthetic serine protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-{alpha} and nitric oxide production and protects mice from lethal endotoxic shock. Innate Immun. 2011;17 (1) :97-105.|[2]Hiwasa T, et al. Potent growth-suppressive activity of a serine protease inhibitor, ONO-3403, toward malignant human neuroblastoma cell lines. Cancer Lett. 1998;126 (2) :221-225.|[3]Ohkoshi M, et al. Growth inhibition of mouse autochthonous skin cancer by oral administration of new serine protease inhibitor ONO-3403. Anticancer Res. 2002;22 (2A) :821-823.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [181586-07-2]